Furthermore, we found that even in a tumor type such as NSCLC, which has previously been reported to have a prevalence of only 20% of patients having any CTCs [18], we were able to capture at least one CTC and quantitate EGFR expression in blood samples from 24 out of 34 patients we evaluated. This evidence concerns the gene EGFR and neoplasm.